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Gillian Wheater1,2*, Mohsen Elshahaly2,3, Stephen P Tuck2,3, Harish K Datta2 and Jacob M van Laar2,3Abstract
Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue, resulting in increased
fragility and susceptibility to fracture. Osteoporotic fractures are a significant cause of morbidity and mortality.
Direct medical costs from such fractures in the UK are currently estimated at over two billion pounds per year,
resulting in a substantial healthcare burden that is expected to rise exponentially due to increasing life expectancy.
Currently bone mineral density is the WHO standard for diagnosis of osteoporosis, but poor sensitivity means that
potential fractures will be missed if it is used alone. During the past decade considerable progress has been made
in the identification and characterisation of specific biomarkers to aid the management of metabolic bone disease.
Technological developments have greatly enhanced assay performance producing reliable, rapid, non-invasive cost
effective assays with improved sensitivity and specificity. We now have a greater understanding of the need to
regulate pre-analytical sample collection to minimise the effects of biological variation. However, bone turnover
markers (BTMs) still have limited clinical utility. It is not routinely recommended to use BTMs to select those at risk
of fractures, but baseline measurements of resorption markers are useful before commencement of anti-resorptive
treatment and can be checked 3–6 months later to monitor response and adherence to treatment. Similarly,
formation markers can be used to monitor bone forming agents. BTMs may also be useful when monitoring
patients during treatment holidays and aid in the decision as to when therapy should be recommenced. Recent
recommendations by the Bone Marker Standards Working Group propose to standardise research and include a
specific marker of bone resorption (CTX) and bone formation (P1NP) in all future studies. It is hoped that improved
research in turn will lead to optimised markers for the clinical management of osteoporosis and other bone
diseases.
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Bone is a specialised connective tissue consisting primarily
of glycoproteins and proteoglycans. The fibres of bone are
mostly composed of type-I collagen impregnated with
mineral in the form of hydroxyapatite. The functional in-
tegrity and strength of the skeleton is maintained by this
highly cross-linked structure. Several factors may be in-
volved in determining bone quality, including bone density
and qualitative determinants of bone strength such as the
rate of bone turnover, the extent of trabecular connec-
tivity, cortical and periosteal bone size and skeletal* Correspondence: gill.wheater@stees.nhs.uk
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reproduction in any medium, provided the ormorphometry [1]. Bone is metabolically active and is con-
stantly being repaired and remodelled throughout an indi-
vidual’s lifetime. Approximately twenty percent of bone
tissue is replaced annually varying by site and type [2]. Re-
modelling begins before birth and continues until death, it
is a highly synchronised process contained within basic
multicellular units (Figure 1). Recent research has demon-
strated the role of receptor activator of nuclear factor
kappa B ligand/ receptor activator of nuclear factor kappa
B/ osteoprotegerin (RANKL/RANK/OPG) in regulating
bone metabolism [3]. Parathyroid hormone (PTH), PTH-
related peptide (PTH-rP), 1,25-dihydroxyvitamin D3, pros-
taglandin E2, and interleukins among others regulate bone
turnover through this system [4]. Additionally, bone
metabolism is now known to be at least partly regulated
by osteocytes, the fully differentiated osteoblasts presentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The bone remodelling cycle. The bone remodelling cycle lasts 150–200 days and is primarily mediated by osteoblastic signals which
promote the differentiation and maturation of osteoclast precursors. Activated osteoclasts create resorption pits with low pH to dissolve the
inorganic matrix and lysomal enzymes, such as TRAP and cathepsin K, effectively digest the exposed type-1 collagen releasing specific
degradation products. Osteoblasts are attracted to this eroded surface and begin to form new osteoid. Type-1 collagen, abundant in osteoblasts,
is secreted as a procollagen precursor molecule into the extracellular space where it is cleaved at the amino- and carboxy-terminals releasing pro-
peptides into the blood. Initially hydroxyapatite crystals are deposited in the osteoid then a slower mineralisation process continues over several
months, followed by a period of quiescence. RANKL, an essential osteoclastogenic cytokine, is expressed on the surface of osteoblasts, it binds to
its cellular receptor RANK on pre-osteoclasts and promotes their differentiation and activation. OPG a decoy receptor for RANKL, is secreted by
osteoblasts and other stromal derived cells and reduces bone resorption by binding to RANK and preventing osteoclastic activity.
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bone [1]. Osteocytes detect mechanical loads and release
signalling molecules (Figure 2) which coordinate the re-
cruitment and activity of osteoblasts and osteoclasts
thereby controlling bone turnover [5].
Under normal conditions bone formation and resorp-
tion are tightly linked through a variety of regulatory
signals. Osteoporosis occurs when bone resorption is
the more active resulting in a low bone mass and micro-
architectural deterioration of bone tissue, leading to in-
creased bone fragility and consequent increase in fracture
risk. Osteoporotic fractures are a significant cause of mor-
bidity and mortality, in the year 2010 there were an esti-
mated 300,000 osteoporotic fractures in the UK and direct
medical costs from such fractures were estimated at over
two billion pounds [8]. Osteoporosis may be either pri-
mary (idiopathic) or secondary to a large number of con-
ditions. These include hypogonadism, hyperthyroidism,
skeletal metastases, multiple myeloma, anticonvulsant or
oral corticosteroid use and alcohol abuse. Up to 30% of
women and 55% of men with symptomatic vertebral crush
fractures have an underlying cause of secondary osteopor-
osis [9]. The prevalence of osteoporosis increases with age,
bone loss is reportedly more rapid in females in the first
few years post menopause and is influenced by oestrogendeficiency [10], but it is also thought to increase in ageing
men [11]. The World Health Organisation (WHO) has
defined osteoporosis as a bone mineral density (BMD)
measured by dual-energy X-ray absorptiometry (DXA)
2.5 standard deviations (SD) or more below the mean peak
bone mass of premenopausal females (T-score ≤ −2.5 SD)
[12]. Technical developments in the measurement of
BMD have led to its adoption as the standard for diag-
nosis of osteoporosis, however the relatively poor sensi-
tivity contrasting with high specificity means that many
potential fractures will be missed if BMD assessment is
used alone [13].
In recent years cellular components of the bone matrix
have been identified and categorised as either markers
of bone formation or resorption. Reliable, rapid, non-
invasive, cost effective assays have been developed with
improved sensitivity and specificity. Although these
markers have been used in research for a long time they
are only now being recognised as tools in the clinical
management of bone disease. Technological advances
have greatly enhanced the accuracy and reliability of
bone marker measurement, although assays still vary
significantly. In this review we will summarise the most
widely used bone turnover makers (BTMs), briefly look
at more novel markers and discuss their strengths,
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Figure 2 Mechanism of blockade of the Wnt signalling pathway by osteocytes. Osteocytes detect changes in bone morphology through
their sensitivity to mechanical forces, thereby regulating bone turnover through direct physical contact with osteoblasts. Osteocytes produce
OPN, DMP, MEPE, SCL and DKK-1. The β-catenin-dependent canonical Wnt signalling pathway controls gene expression by stabilizing β-catenin
in regulating a diverse array of biological processes. It is initiated by binding of appropriate Wnt ligands to the frizzled (Fz) and low-density
lipoprotein receptor-related proteins 5 and 6 (LRP-5/6) and can be antagonized by secreted proteins from SCL and the DKK family, that bind
with high affinity to LRP-5 or LRP-6, thereby directly prevent Wnt binding. Wnt proteins act on osteoblast precursor cells through this pathway
and promote their differentiation into mature osteoblasts. In addition, they can suppress bone resorption by up-regulating OPG and down-
regulating RANKL expression in mature osteoblasts, leading to a net increase in bone mass [6]. Additionally research has targeted the complex
regulation of osteocyte action by expression of PTH/PTHrP receptor’s (PPR’s). Osteocyte activation of PPR leads to down-regulation of Sost and
increased Wnt signalling stimulating bone formation, accompanied by up-regulation of RANKL expression and osteoclast number increasing
resorption. In contrast the main effect of PPR deletion on osteocytes is reduced osteoclast and osteoblast numbers and decreased bone
remodelling [7].
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of osteoporosis.Commonly used markers of bone turnover
Biomarkers of bone turnover can be measured in blood or
urine and are used in selective combinations of formation
and resorption markers that express the metabolic activity
of osteoblasts or osteoclasts respectively, although in most
circumstances the bone remodelling processes are coupled
and tend to change in parallel. BTMs do not control skel-
etal metabolism and are not disease specific; they reflect
the entire skeleton regardless of the underlying cause.
Some markers represent both processes, e.g. osteocalcin
(OC). Several of the available markers are non-specific, i.e.
they are present in tissues other than bone and may there-
fore be influenced by non-skeletal processes [14]. Results
should therefore always take into consideration the whole
clinical picture and an understanding of the nature and
source of each marker is essential for a comprehensive in-
terpretation. The major advantages and disadvantages of
each marker are included in Table 1.Markers of bone formation
Markers of bone formation are either by-products of
active osteoblasts expressed during the various phases
of their development or osteoblastic enzymes. The
most widely used markers of bone formation are mea-
sured in serum or plasma and include: bone specific
alkaline phosphatase (BSAP), osteocalcin and the
carboxy- and amino-terminal propeptides of type 1
collagen (P1CP, P1NP). P1NP has several functional
advantages and has been recommended by the Bone
Marker Standards Working Group; it has low inter-
individual variability [20] and is relatively stable in
serum at room temperature [21]. P1NP is cleared by
liver endothelial cells via a macrophage receptor spe-
cies, the scavenger receptor, that recognises and endo-
cytoses modified proteins [37]. P1NP is released as a
trimeric structure, but is rapidly broken down to a
monomeric form by thermal degradation [38]. Current
immunoassays detect either the trimeric ‘intact’ mol-
ecule (automated IDS iSYS assay) or can measure both
fractions and are thus called ‘total’ P1NP assays (auto-
mated Roche Elecsys assay).
Table 1 Major sources of variability in biochemical markers of bone turnover
Bone marker
(Abbreviation)
Source Action Advantages Disadvantages Analysis and sample
type
Formation markers
Bone Alkaline
Phosphatase (BAP)
Enzyme present in
osteoblast plasma
membranes
Enzymatic degradation of the
mineralisation inhibitor
pyrophosphate at alkaline pH
Low intra-individual variability <10% [15]
Not affected by renal function [15] Food
has little effect [16] Long circulatory half-life
1–2 days [17] Sample stability [18] Cheap
Up to 20% cross reactivity with liver
isoforms [14] Changes with therapy minimal
i.e. less than LSC of 25% [15] 2 peaks at
14:00 and 23:30 hrs Nadir 30% ↓at 06:30 [19]
Multiple methodologies, can measure mass
or activity [20]
Automated and manual
immunoassays Serum,
EDTA plasma
Osteocalcin (OC) Major non-collagen bone
Gla protein. Produced by
osteoblasts during bone
formation and bound to
hydroxyapatite
Influences osteoid
mineralisation Provides
negative feedback during
remodelling process
EDTA sample more stable [21] Late marker
of osteoblast activity [15]
Intact molecule unstable [15] Large inter-lab
variation [20] Released during formation and
resorption [17] Short half-life of a few
minutes [22,23] Influenced by Vit K status,
renal function and circadian variability
[15,17] OC gene regulated at transcriptional
level by 1,25-OH2 Vit D Vit K essential co-
factor for γ-carboxylation of OC resulting in
↑ affinity for Ca and hydroxyapatite [14]
Automated and manual
immunoassays Multiplex
microarray Serum, EDTA
plasma
Procollagen type
1 Carboxy-
terminal
Propeptide (P1CP)
Specific product of
proliferating osteoblasts
and fibroblasts.
Cleaved from type 1 pro-
collagen by proteases during
type 1 collagen formation
Quantitative measure
of newly formed type
1 collagen
Thermostability [14]
Short half-life 6-8mins [14] Cleared in liver
by mannose receptor so sensitive to thyroid
hormones and IGF-1 [20] Highest levels
01:30 – 04:30, up to 20% higher than nadir
11:00 – 15:00 [19] Lacks sensitivity to
changes during menopause [14]
Automated and manual
immunoassays Serum,
EDTA plasma
*Procollagen
type 1 amiNo-
terminal
Propeptide
(P1NP)
Specific product of
proliferating osteoblasts
and fibroblasts.
Cleaved from type 1 pro-
collagen by proteases
during type 1 collagen
formation
Low intra-individual variability [20]
Small circadian rhythm [15] Stable at
room temp [21] Good assay precision
[20] Superior for PMO monitoring -
change from baseline ↑up to 80% with
anti-resorptive and ↓up to 200% with
PTH medication within 3months [15]
Total assay affected by delayed
clearance of monomeric fraction e.g. in
renal failure or metastatic bone disease
[24] Expensive
Automated and manual
immunoassays
Multiplex microarray
Total or Intact fractions
Serum, EDTA plasma
Resorption markers
Collagen derived
*Carboxy-
Terminal cross-
linked
telopeptides of
type 1 collagen
(CTX)
Type 1 collagen mainly
bone Isomerisation to β
aspartyl occurs in
mature collagen
Cleaved from type 1
collagen by cathepsin-K
during bone resorption
Variability↓ fasting [25] Sample stability,
especially EDTA [18,21] Substantial ↓
post anti-resorptive treatment [26]
Blood sample now preferential
Large circadian variation – highest 01:30
– 04:30 approx 2x nadir 11:00–15:00 [27]
Automated and manual
immunoassays
Multiplex microarray
Urine, serum, EDTA
plasma
Carboxy-Terminal
cross-linked
telopeptides of
type 1 collagen
(ICTP or CTX-MMP)
Newly synthesised type 1
collagen predominantly
bone
Cleaved from type 1 collagen
by MMP during bone
resorption
Large circadian variation [20] Influenced by
renal and liver function [20] Not responsive
to usual osteoporotic treatments [20]
Manual immunoassay
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Table 1 Major sources of variability in biochemical markers of bone turnover (Continued)
amiNo-Terminal
cross-linked
telopeptides of
type 1 collagen
(NTX)
Type 1 collagen mainly
bone
Cleaved from type 1 collagen
by cathepsin-K during bone
resorption
Urine sample stable [15] uNTX sig predictor
of fracture risk in postmenopausal women
[28] Small dietary influence, although
fasting blood sample preferred [15]
Large circadian variation Influenced by renal
and liver function [20] Units based on
manufacturer’s calibrator i.e. bone collagen
equivalents [15]
Automated and manual
immunoassays Urine,
serum, EDTA plasma
Type 1 collagen
alpha 1 helicoidal
peptide (HELP)
Type 1 collagen Amino
acid 620–633 sequence of
the α chain
Cleaved from helical region of
type 1 collagen by cathepsin-
K during bone resorption
High correlation to other markers of
collagen degradation [14]
24 hr collection – hard to collect 2nd
morning void with creatinine correction –
additional analytical variability Clinical
validity needs further investigation
Manual immunoassay
Urinary marker
Deoxypyridinoline
(DPD)
Mature type 1 collagen Cross link released when
mature type 1 collagen breaks
down Mechanically stabilise
the molecule
Reflect degradation of mature collagen
only Specific to bone [14] Independent of
dietary sources [20] Less invasive than
blood
24 hr collection – hard to collect 2nd
morning void with creatinine correction –
additional analytical variability Circadian
variation [20]
Automated and manual
immunoassays Urinary
marker
Pyridinoline (PYD) Mature type 1 and 11
collagen
Cross link released when
mature collagen type 1 and
11 breaks down Mechanically
stabilise the molecule
Reflect degradation of mature collagen
only Independent of dietary sources [20]
Non-specific 24 hr collection – hard to
collect 2nd morning void with creatinine
correction – additional analytical variability
Circadian variation [20] Influenced by liver
function [20]
Automated and manual
immunoassays Urinary
marker
Resorption markers
Osteoclastic Enzymes
Tartrate Resistant
Acid Phosphatase –
isoform 5b
(TRAP5b)
Isoform of acid
phosphatase, resistant to
tartrate, cleaved by
proteases into 5b, present
in ruffled border of
osteoclasts
Cleaves type 1 collagen into
fragments
Characteristic of osteoclastic activity [14] Unstable at room temperature [22,23]
Circadian variability ↑ immediately after
exercise [29]
Automated and manual
immunoassays Serum
Cathepsin K Cysteine protease present
in ruffled border of
actively resorbing
osteoclasts
Cleaves telopeptide and
helical regions of type 1
collagen
Specific biomarker of osteoclastic activity [14] Unstable at room temp Clinical validity
needs further investigation
Manual immunoassay
Serum, EDTA plasma
Osteocyte activity markers
Receptor Activator
of Nuclear factor
Kappa B Ligand
(RANKL)
Produced by osteoblasts,
activated by B and T cells
Binds to RANK, which is
expressed on osteoclasts and
their precursors, stimulating
their differentiation and
activity
Novel biomarker Provide safety, efficacy
and pharmacokinetics data to confirm drug
mechanisms and mode of action for future
use
Analytical problems Can measure free or
OPG-bound [30] Circulating levels may not
reflect bone microenvironment [31] Affected
by thyroid function [32] Research method
only Clinical and analytical validity needs
further investigation
Manual research –grade
immunoassay Total or
soluble forms in serum
Osteoprotegerin
(OPG)
Secreted by osteoblasts Decoy receptor to RANKL
reduces bone resorption by
binding to RANK and
preventing osteoclastogenesis
Novel biomarker Provide safety, efficacy
and pharmacokinetics data to confirm drug
mechanisms and mode of action for future
use
Affected by thyroid function [32] Research
method only Clinical and analytical validity
needs further investigation
Manual research-grade
immunoassay Serum
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Table 1 Major sources of variability in biochemical markers of bone turnover (Continued)
Dickkopf-related
protein 1 (DKK1)
Produced by osteocytes Inhibition of Wnt signalling
pathway through binding to
LRP5/6, blocking the Wnt
effects on osteoblasts and
decreasing bone formation
Key role in regulation of bone turnover Research method only Clinical and analytical
validity needs further investigation
Manual research –grade
immunoassay Serum
Sclerostin (SCL) Secreted by osteocytes Inhibition of Wnt signalling
pathway through binding to
LRP5/6, blocking the Wnt
effects on osteoblasts and
decreasing bone formation
Significant ↓ with PTH therapy [33] Research method only Affected by
immobility [34] ↑ in type 1 and 2 diabetes
[35,36] Clinical and analytical validity needs
further investigation
Manual research-grade
immunoassaySerum
*P1NP and CTX (highlighted in bold) are the markers of choice, recommended by the IOF, IFCC (2011) and NBHA (2012).
ALP alkaline phosphatase, BSAP bone specific alkaline phosphatase, CTX carboxy-terminal cross-linked telopeptides of type 1 collagen, DKK-1 dickkopf-related protein 1, DPD deoxypyridinoline, EDTA ethylenediaminetetraacetic
acid, HELP Type 1 collagen alpha 1 helicoidal peptide, ICTP carboxy-terminal cross-linked telopeptide of type 1 collagen, IGF-1 insulin-like growth factor-1, LRP low-density lipoprotein receptor-related protein, MMP matrix
metalloproteinases, NTX amino-terminal cross-linked telopeptide of type 1 collagen, OPG osteoprotegerin, OC osteocalcin, PICP procollagen type 1 carboxy-terminal propeptide, PINP procollagen type 1 amino-terminal
propeptide, PYD pyridinoline, RANK receptor activator of nuclear factor kappa B, RANKL receptor activator of nuclear factor kappa B ligand, SCL sclerostin, TRAP tartrate resistant acid phosphatase.
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The majority of bone resorption markers are degradation
products of bone collagen, the exception being tartrate-
resistant acid phosphatase (TRAP5b). Earlier research into
bone metabolism relied primarily on urinary markers such
as pyridinoline (PYD) and deoxypyridinoline (DPD), which
were time-consuming and cumbersome and relied on
complete twenty-four hour urine collections or second
morning void/ creatinine ratios, increasing the imprecision
of the measurement. However, now that serum/ plasma
markers are available these have become the preferred
means of measuring resorption. Examples include carboxy-
terminal and amino-terminal cross-linked telopeptide of
type 1 collagen (CTX and NTX respectively), of which
CTX is considered the marker of choice [20]. CTX is gen-
erated by cathepsin K activity, the CTX epitope contains an
aspartyl-glycine motif that is susceptible to spontaneous
isomerisation and racemisation generating four isoforms
[17]; the α-aspartic acid converts to the β-form as the bone
ages. Two automated immunoassays are available that
target βCTX indicative of the breakdown of mature type 1
collagen (IDS iSYS and Roche Elecsys). The major disad-
vantage of CTX is its large circadian variation necessitat-
ing a morning fasting sample for accurate interpretation
[25]. The choice of marker in clinical practice needs to be
made on pragmatic grounds. Urine NTX may be the
preferred marker in the clinic setting as unlike plasma
CTX, it is not as sensitive to circadian changes and is not
affected by food intake, it also avoids the invasive vene-
puncture associated with a blood sample and may be pre-
ferred by patients [39]. However the various drugs
licensed for the treatment of osteoporosis have a differing
spectrum of effects on BTMs and not all markers respond
by the same amount for a given degree of bone resorption.
Amongst the bone resorption markers, plasma CTX tends
to change more than urine NTX which tends to change
more than TRAP5b [20].
Markers of osteoclastogenesis
Osteoclast regulatory proteins are commonly measured
in research, but have yet to find a niche clinically. The
discovery of the OPG/RANK/RANKL system has clari-
fied a major component of the bone remodelling cycle.
RANKL is expressed in vivo in either membrane-bound
or soluble form (sRANKL) and is also present in serum
as a free or OPG-bound molecule, as a consequence de-
sign differences between immunoassays have created dif-
ficulties in comparing research and interpreting clinical
data [30]. Furthermore circulating levels may not reflect
the bone microenvironment [31]. Research into the rela-
tionship between circulating levels of OPG and sRANKL
to BMD in postmenopausal osteoporosis are controversial,
some studies reporting an inverse relationship [40], while
others have found no association [41]. Rigorous testing ofcommercial assays and identification of the sources of
variability are required before they can be adapted to
routine clinical practice.
Osteocyte markers
Over the last decade research has focused mainly on the
role of osteoclasts and osteoblasts in osteoporosis, more
recently however, osteocytes have been found to play a
key role in the regulation of bone turnover. Osteocytes
are fully differentiated osteoblasts and lie in lacunae in
the mineralized matrix and osteoid tissue of bone [42].
Osteocytes are able to detect changes in bone morphology,
particularly micro-fractures through their sensitivity to
mechanical forces, acting like bone mechanoreceptors
[43]. They regulate bone turnover both through direct
physical contact with other bone cells and by producing
various factors which affect bone formation and can be
measured in blood such as, sclerostin (SCL), dickkopf-
related protein 1 (DKK1), dentin matrix protein 1 (DMP1)
and matrix extracellular phosphoglycoprotein (MEPE).
DKK1 and SCL are secreted osteocyte markers acting as
inhibitors to the Wnt signalling pathway through binding
to low density lipoprotein receptor-related protein 5 and 6
(LRP5/6) and hence blocking the Wnt effects on osteo-
blasts decreasing bone formation (Figure 2) [44,45]. In
vivo studies have shown that osteocyte depletion results in
profound loss of trabecular bone mass [46-48] and suggest
a close interaction between osteocytes and other bone
cells, highlighting their role in the regulation of both bone
formation and resorption.
Although widely used in research, their diagnostic im-
portance remains to be validated due in part to their
analytical and biological variability. In healthy adults,
SCL levels correlate positively with age, BMI, and bone
mineral content and negatively with osteocalcin and cal-
cium [49]. SCL is increased in type 2 diabetes. More-
over, the transcriptional suppression of SCL production
by PTH might be impaired in type 1 and type 2 diabetes
[35]. SCL levels are significantly lower in osteoporotic
compared to non-osteoporotic patients with type 2 dia-
betes [36]. The Wnt signalling pathway has recently
been identified as central to the development of disuse
osteoporosis [50]. Mechanical unloading in long-term
immobilized patients causes up regulation of SCL and
therefore inhibits bone formation via suppressed osteo-
blast activity and survival [34]. Circulating SCL reflects
the severity of bone loss and is a candidate biomarker of
osteoporosis severity in chronic spinal cord injury [51].
Higher serum SCL levels are associated with a greater
risk of hip fractures in older women. In addition, the
risk of hip fracture is amplified when high SCL levels
are combined with lower BMD [52]. Serum SCL levels
are regulated by both estrogens and PTH in postmeno-
pausal women [53]. Serum SCL is decreased in women
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osteoporotic early postmenopausal women and positively
correlated to lumbar spine BMD. Furthermore, levels are
increased after 6 months treatment with risedronate, but
remain essentially unchanged after 6 months teriparatide
treatment [54]. However, serum or plasma SCL concen-
trations should be interpreted with caution as current
assays produce very different results. Standardization of
sclerostin assays is necessary before being introduced
into general clinical laboratory use [55].Variability in markers of bone turnover
An understanding of the source and magnitude of the
absolute inter and intra-person variability, including
biological, pre-analytic and analytical variation, of each
marker is necessary to interpret serial measurements
and individualise treatment.Biological variability
Intra-individual variation Bone turnover shows a circa-
dian rhythm, this is more obvious in the serum and urin-
ary markers of bone resorption. βCTX for example is
highest between 01:30 and 04:30 hours and may be more
than twice that at the nadir between 11:00 and 15:00 hours
[27], this may be attenuated by several factors such as; age,
gender, ethnicity, menopausal status, osteoporotic stage
and anti-resorptive agents or calcium supplementation
[19], but the disparity is diminished with fasting [25]. All
bone markers are significantly lower in the fed state with
the exception of BSAP, this may be due to several factors
including the clearance rate of individual markers or food
composition [16] and may be partly explained by variation
in serum insulin [25]. Osteocalcin and P1CP follow the
same diurnal pattern but show only twenty percent differ-
ence and BSAP has two peaks at 14:00 and 23:30 hours
with a nadir thirty percent reduced at 06:30 [19]. There-
fore timing of the sample collection and fasting status
should be tightly controlled.
The existence of intra-individual low-frequency bio-
logical rhythms, imply that biomarkers can also vary
between consecutive days, this is more noticeable in
the urinary resorption markers [14]. There is a degree
of controversy regarding seasonal variation with some
researchers suggesting that overall seasonal changes
are insignificant [56], whilst others have found a sub-
stantial wintertime increase [57], which may be due in
part to reduced levels of vitamin D. Physical activity is
also significant, TRAP and to a lesser extent BSAP and
CTX are reduced immediately after plyometrics, but
return to pre concentrations within two hours. Inter-
estingly similar changes were found in PTH [29]. De-
tails of exercise in the previous twenty-four hours
should therefore be recorded.Bone turnover varies with the menstrual cycle, research
suggests that osteoblastic activity is higher during the lu-
teal period [58] and bone resorption is increased during
the follicular phase [59]. Pregnancy affects all BTMs due
in part to the calcium requirements of the foetus, but
also to changes in maternal glomerular filtration rate
(GFR) affecting renal clearance. However the time
change is contentious, one study following ten women
at regular intervals reported an increase in urinary resorp-
tion markers throughout pregnancy with a significant
increase in bone formation in the third trimester [60]. A
more recent study measured serum OPG, RANKL,
osteocalcin and CTX in twenty six different women at
each trimester. The study found increased bone formation
in the first trimester and increased resorption in the sec-
ond which surprisingly decreased again in the third tri-
mester [61]. Postpartum, levels gradually start to decrease
but may still be higher than pre-pregnancy levels for up to
a year [62].
A comprehensive drug history should also be taken
into account when interpreting bone marker results.
Anti-resorptive drugs such as bisphosphonates [26] and
hormone replacement therapy (HRT) [63] have a major
effect on markers of bone resorption and long-term
corticosteroid therapy is known to suppress bone for-
mation [64].
Inflammatory conditions are major precipitators for
bone loss, especially rheumatoid arthritis (RA) which is
further aggravated by decreased functional activity and
the use of glucocorticoids [65]. In a prior study, we
found that B-cell depletion increases bone formation
and decreases bone resorption in RA patients. This may
be a direct effect on osteoblasts and osteoclasts respect-
ively and be at least partially explained by the decreased
inflammation and disease activity [66]. In diabetes serum
osteocalcin is negatively correlated with glucose levels
and advanced glycation end products (AGEs) are known
to have a negative impact on bone [67]. Thyroid disorders
such as thyrotoxicosis are well known to affect bone turn-
over. Thyroid stimulating hormone (TSH) receptors are
present in both osteoblasts and osteoclasts and the low
TSH levels observed in thyroidectomised patients on
L-thyroxine are associated with an increase in OPG and
decrease in RANKL and are significantly correlated with
vertebral fractures [32]. Bone markers are cleared through
the liver or kidneys and are also influenced by diseases
affecting these systems, decreased GFR for example will
decrease the urinary excretion of CTX and therefore in-
crease serum levels. They are also affected by any disease
states leading to increased periods of bed rest and immo-
bility. Research has shown that microgravity induces
significant and progressive bone loss, a consequence of in-
creased bone resorption and retardation of bone forma-
tion [68]. Certainly levels of all bone markers increase
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remain elevated for up to a year. The rate of increase is
dependent on the location, severity and size of the fracture
and the age of the patient. BTM’s can be elevated for up to
6 months after minor fractures e.g. forearm fractures but
up to one year after a hip fracture and needs to be taken
into consideration when measuring them [19,69]. How-
ever, they fall gradually over time and using a reduction of
50% in bone resorption when using anti-resorptives as a
good indicator of response would be greater than any
reduction that might otherwise occur.
In light of the above evidence it can be seen that to use
bone turnover to monitor change can be quite difficult. In
order to minimise problems it is best to measure the
BTMs in as similar a set of circumstances as possible. Par-
ticular attention should be paid to the time of day and
hence research studies tend to use early morning fasted
samples. One way in which to help overcome within per-
son variability in serial measurements and to monitor
therapy is to use the ‘least significant change’ (LSC) model
[70]. LSC at a significance level of p=<0.05 is defined as
1.96*√2*√ (CV1
2+CVA
2); where CV1 is the within-subject
coefficient of variation and CVA is the total analytical
imprecision. LSC identifies the true physiological change
in the marker. In general a change of more than twenty
percent is considered significant for formation markers
[71], similarly between twenty-seven to thirty-six percent
is significant for markers of bone resorption [72].
Inter-individual variation Between person variability is
much harder to control, e.g. age, gender, and menopausal
status, but is equally important to validate results. Bone
metabolism rates are higher in infants up to three years of
age, they are relatively stable throughout adolescence but
sex-specific increases in bone marker levels are evident
during the pubertal growth spurt and are reportedly
influenced by pubertal stage rather than age [73]. BTMs
are higher in men between twenty and thirty years of age
then reach their lowest levels during their fifties [14],
whereas in females there is a substantial increase in bone
turnover corresponding to oestrogen deficiency during the
menopause [28]. We checked our local population and
found a trend towards higher bone turnover in males
during their third decade whilst reaching peak bone mass,
although there seemed to be little evidence of any age re-
lated change in women possibly due to the lower numbers
of postmenopausal females in our cohort (Figure 3). It is
important for each laboratory to investigate the transfer-
ability of the quoted reference intervals to its own patient
population based on equivalent standardised collection
conditions. The widespread availability of automated im-
munoassays now means that harmonisation of method
specific reference ranges is possible and studies from well-
characterised populations have reported robust BTMranges in large well defined cohorts [74]. In contrast to
the use of reference ranges some researchers have sug-
gested combining a marker of formation and resorption to
gain a direct insight into the changes in the balance and
rate of bone turnover in relation to a reference value [75],
leading factors in estimating fracture risk and prognosis.
Given the large observed differences observed between
genders, different ages and developmental stages means
that care must be taken when comparing populations and
in the design of research studies.
Analytical variability
Technical variation Over the last decade many of the
traditional BTM immunoassays have been automated, im-
proving technical performance and increasing their avail-
ability. Nevertheless, analytical aspects such as within and
between batch precision, accuracy and standardisation, re-
main problematic. Inter-laboratory variation is also crucial;
a European study in 2001, measuring pooled samples of
serum and urine in seventy-three laboratories concluded
that even with identical assays results for the majority of
the markers were significantly different [76]. Similarly an
American study in 2010 comparing six commercial
laboratories over an eight month period concluded that
reproducibility varied substantially for urine NTX and
serum BSAP [77]. Moreover there is an extensive list of
bone markers being offered making it very difficult to
compare research evidence. Consequently, the Inter-
national Osteoporosis Foundation (IOF), the International
Federation of Clinical Chemistry and Laboratory Medicine
(IFCC) [20] and the National Bone Health Alliance
(NBHA) [78], have recommended that a marker of bone
formation and resorption, namely P1NP and CTX, are
used as reference analytes in clinical studies. They go on
to stipulate that these markers should be measured by
standardised assays to minimise immunochemical hetero-
geneity and recommend that manufacturers adopt inter-
national reference standards and minimise batch to batch
variability [20].
Sample stability Appropriate control of sample collec-
tion and preparation is vital for successful BTM measure-
ment. Several BTMs, especially osteocalcin and TRAP5b,
are sensitive to thermo degradation and levels can be
significantly reduced after only a few hours at room
temperature [22,23]. TRAP5b activity is also reduced dur-
ing storage, samples must be kept at −70°C or lower and
multiple freeze-thaw cycles should be avoided. No signifi-
cant decrease has been detected in CTX stored at −20°C
or lower for up to three years, nevertheless it rapidly de-
creases in serum at both 4°C and 37°C. The molecular
mechanism is unknown but this decrease is minimised by
ethylenediaminetetraacetic acid (EDTA) [18]. CTX is
reportedly stable in EDTA blood tubes before separation
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stable for up to eight hours at room temperature [21].
Consequently blood should be collected into EDTA tubes
and separated as soon as possible, if samples are not
analysed immediately they should be stored at −20°C or
lower. Both P1NP and BSAP were found to be stable in
any sample type [21]. Notably current TRAP5b assays
are not affected by haemolysis, but erythrocytes are
known to contain proteases which degrade osteocalcin.
Grossly haemolysed samples in general should always
be avoided.
Clinical usefulness of bone turnover markers in
osteoporosis
BTMs are frequently used in clinical trials and provide
valuable information on the efficacy of osteoporotic
treatments, but their predictive value is limited by their
large biological variation and diagnostically they are less
often used for individualized patient care. Other routine
laboratory investigations are frequently used to identify
or exclude secondary causes of osteoporosis such ashyperparathyroidism, vitamin D status, thyrotoxicosis
and hypogonadism [79].
Diagnostic
Currently the WHO recommends the use of BMD of
the spine and proximal femur measured by DXA as the
gold standard to diagnose osteoporosis and its severity
[12]. Although BMD has methodological limitations
especially in the elderly due in part to degenerative
changes in the lumbar spine [80], BTMs alone would
not be suitable to estimate bone loss.
Prediction of bone loss
Women generally lose about one to two percent of their
bone per year after the menopause, however thirty per-
cent lose bone at a faster rate [28]. Longitudinal studies
of post-menopausal women have demonstrated two
characteristic groups; high bone turnover and normal or
low bone turnover. Serial BTM measurements are effect-
ive in identifying those women who lose bone most rap-
idly, this is important because this group respond more
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meta-analysis of eighty-five studies reported a significant
correlation between serial levels of BTMs and BMD
measurements during bisphosphonate treatment [82],
the association becomes stronger with advancing age
[83]. However, BTMs should only be used to supplement
BMD not measured in isolation.
Prediction of fracture risk
BMD is widely used to predict osteoporotic fractures but
approximately thirty to fifty percent of patients with
fragility fractures have T-scores above the osteoporotic
threshold [84]. There is evidence that high bone turn-
over, as measured by a single or combination of BTMs, is
associated with an increased fracture risk [28], but their
use alone to predict fracture has yet to be established.
Two clinical risk assessment algorithms have been vali-
dated for use in the UK to predict fracture incidence over
ten years [85], namely FRAX and QFracture, currently
they do not include all risk factors. BTMs have not been
included because of their inconsistency in research studies
so far. There is a need for studies confirming whether the
addition of BTMs to FRAX would result in increased
sensitivity and specificity.
Treatment selection and monitoring
BMD and BTMs are independent predictors of fracture
risk, recent evidence does not support the use of BTMs
to select the optimal treatment, but BTMs can be used
to monitor treatment efficacy before BMD changes can be
evaluated. Additionally early changes in BTMs can be used
to measure the clinical efficacy of an anti-resorptive treat-
ment and to reinforce patient compliance [26]. The effect-
iveness of osteoporotic therapy can be assessed by serial
BMD measurements usually by DXA, but quantifiable
changes in bone mass are small and are only apparent
after twelve to twenty-four months, furthermore they only
measure net balance in a very small portion of the skel-
eton. DXA reproducibility is also affected by machine and
operator error plus patient variability (weight or degenera-
tive changes) [86]. The minimum acceptable precision for
an individual technician is 1.9% (LSC 5.3%) at the lumbar
spine and 1.8% (LSC 5.0%) at the total hip. Intervals be-
tween measurements depend on the patient’s clinical
status, but given the need to exceed the LSC and the
relatively modest changes in BMD observed with most
treatments it is generally going to be a minimum of two
years before a significant change can be observed. In-
deed, there are trends for a variety of reasons towards
less frequent measurement of BMD to three or even five
year intervals [87].
Meta-regression analysis has found no evidence of a
relationship between BMD changes and reduction in risk
of fractures among patients receiving calcium with orwithout vitamin D supplementation. Calcium and/or
Vitamin D may reduce fracture rates through a mechan-
ism independent of bone density [13]. BTMs on the other
hand show a substantial and more immediate global effect,
they measure both bone formation and resorption rate
and can classify patients into low or high remodelling
groups. Osteoporosis treatments such as bisphosphonates,
strontium ranelate, denosumab, hormone replacement
therapy (HRT) and selective estrogen receptor moderators
(SERMs) act by reducing BTM levels by forty to sixty per-
cent within three to six months [88]. Thus one use of
BTMs is to give an early indication of the success of the
treatment. Baseline measurements can be repeated at the
next follow up appointment say three to six months later.
A significant change in BTMs as assessed by the LSC
method can then be used to judge success of the treat-
ment and will hopefully be reflected by an increase in
BMD in the fullness of time. In the meantime the change
in BTM supplies reassurance to the clinician and can be
used to encourage the patient. Unfortunately, as BTMs are
highly variable this is at best only an indication.
There has been considerable discussion about how long
to treat with bisphosphonates, because these drugs accu-
mulate in the skeleton, leading to a reservoir that con-
tinues to be released for months or years after treatment
has stopped. These medications also result in a low bone
turnover state over time with both resorption and forma-
tion reduced. This combined with concerns over micro-
fracture, the possibility that they may prevent bone
healing and the association with atypical femoral shaft
fractures has led to the belief that it may not be wise to
continue these medications indefinitely. It is generally ac-
cepted that the need to continue bisphosphonates be
reviewed after 5 years and kept under review until ten
years of treatment. Depending on the individual circum-
stances a decision to stop treatment, give a drug holiday
or change treatment may be made. If a drug holiday is de-
cided upon then BTMs could be checked at regular inter-
vals, e.g. annually. Once these are rising again and
especially on return to pre-treatment levels therapy could
be restarted. Such an approach may be particularly useful
with longer acting agents such as zoledronic acid [89].
The BTMs should be used in conjunction with the clinical
circumstances and with repeated BMD after appropriate
time intervals.
More recently anabolic agents such as PTH, e.g.
teriparatide, have become available which stimulate
osteoblastic activity. Markers of bone formation in-
crease early after the initiation of teriparatide therapy
with a delayed, but significant, increase in resorption
markers [90]. It has been proposed clinically to measure
P1NP at baseline and three months post treatment a
positive response is defined as a change of greater than
10 μg/L [91].
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During the last decade significant advances have been
made in the identification and characterisation of
specific BTMs for use in clinical drug trials and to aid in
the therapeutic management of osteoporosis. Techno-
logical developments have greatly enhanced assay per-
formance producing reliable, rapid, non-invasive cost
effective assays with improved sensitivity and specificity.
We now have a greater understanding of the need to
regulate pre-analytical sample collection to minimise
the effects of biological variation. The use of BTMs
to select those at risk of fractures is not routinely
recommended partly due to their degree of variability.
However, baseline measurements of resorption markers
are useful before commencement of anti-resorptive treat-
ment e.g. bisphosphonates or denosumab and can be
checked 3–6 months later to check response and adher-
ence to treatment. Similarly a formation marker such as
P1NP can be used to monitor bone forming agents such
as PTH analogues. BTMs may also be useful when moni-
toring patients during treatment holidays and aid in the
decision as to when therapy should be recommenced. The
recent recommendations by the Bone Marker Standards
Working Group aim to standardise research and include a
marker of bone resorption (CTX) and formation (P1NP)
in all future studies. They anticipate that manufacturers
will calibrate their assays in future using an international
reference standard to establish robust reference ranges. It
is hoped that improved research in turn will lead to opti-
mise markers for the clinical management of osteoporosis
and other bone diseases. The biochemical assessment, util-
izing BSAP, is now the mainstay of the diagnosis and
management of metabolic bone disease in chronic kidney
disease.
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